OCI-M2Homo sapiens (Human)Cancer cell line
Also known as: OCIM2, OCI M2
🤖 AI SummaryBased on 4 publications
Quick Overview
Human cell line with JAK2 V617F mutation for leukemia research.
Detailed Summary
The OCI-M2 cell line is a human cell line derived from a patient with myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS). It carries the JAK2 V617F mutation, a key driver in myeloproliferative disorders. This cell line is used to study the molecular mechanisms of JAK2 mutations and their role in leukemogenesis. Research on OCI-M2 has contributed to understanding the pathogenesis of MPD and MDS, particularly in relation to JAK2 signaling pathways. The cell line is also utilized to evaluate the efficacy of JAK2 inhibitors in therapeutic strategies.
Research Applications
Study of JAK2 V617F mutation in myeloproliferative disordersInvestigation of JAK2 signaling pathways in leukemogenesisEvaluation of JAK2 inhibitor efficacy
Key Characteristics
JAK2 V617F mutationRelevance to MPD and MDSUse in JAK2 inhibitor studies
Generated on 6/18/2025
Basic Information
| Database ID | CVCL_2150 |
|---|---|
| Species | Homo sapiens (Human) |
Donor Information
| Age | 56 |
|---|---|
| Age Category | Adult |
| Sex | Unknown |
Disease Information
| Disease | Acute myeloid leukemia |
|---|---|
| Lineage | Myeloid |
| Subtype | Acute Myeloid Leukemia |
| OncoTree Code | AML |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-001618_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Val274Asp (c.821T>A) | Unspecified | - | Unknown |
| MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
| Gene fusion | RUNX1 | RUNX1-TSPEAR | - | - | PubMed=31160637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
10,12
D13S317
11,14
D16S539
11
D18S51
16,20
D19S433
14
D21S11
29
D2S1338
18,24
D3S1358
15
D5S818
11,12
D7S820
8,11
D8S1179
10,13
FGA
21
Penta D
9
Penta E
10,12
TH01
8,9
TPOX
8
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations.
Messner H.A.
Blood 72:1029-1038(1988).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).